Clinical
Tremfya launched for psoriasis
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.Bookmark
Record learning outcomes
Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Janssen says that guselkumab is the first biologic to “selectively target interleukin-23, a key protein that initiates a specific immune inflammatory responseâ€.